MoneycontrolMoneycontrol

Neutral Torrent Pharma; target of Rs 4970: Motilal Oswal

阅读少于1分钟

Motilal Oswal's research report on Torrent Pharma

Torrent Pharma (TRP) delivered slightly better-than-expected revenue/EBITDA (+3%/5%) for the quarter. Earnings were largely in line with estimates due to higher-than-expected tax rate for the quarter. TRP outperformed domestic formulation industry (IPM) growth by a wide margin, led by market share gains in chronic therapies, robust scale-up of Curatio portfolio, and healthy market share in the Semaglutide product. Notably, TRP outpaced the Brazilian branded generics market, led by new launches, volume growth, pricing, and inventory normalization.

Outlook

We value TRP at 52x 12-month forward earnings to arrive at a TP of INR4,970. We remain constructive on TRP's domestic growth prospects, expanding Semaglutide opportunity and potential earnings benefits from JB Pharma integration.

免责声明

阅读全文
在TradingView,您可以无限访问来自Moneycontrol和所有其他新闻来源的文章。